RecruitingPhase 2

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

United States49 participantsStarted 2024-02-01

Plain-language summary

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Not a woman of childbearing potential (WOCBP) as defined in section 15.3 OR
✓. A WOCBP who agrees to follow the contraceptive guidance in section 15.3 during the treatment period and for at least 170 days (140 days plus an additional 30 days \[menstruation cycle\]) after the last dose of study treatment.

What they're measuring

Event-free survival (EFS)

Timeframe: 2 years

Trial details

NCT IDNCT06123338

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11-30

Contact for this trial

Yelena Janjigian, MD

646-888-4186 janjigiy@mskcc.org

View on ClinicalTrials.gov More Esophageal Cancer trials